2016-04-17T14:17:46+05:302016-04-17T14:17:36+05:302016-04-17T14:17:46+05:30Acrobat PDFMaker 11 for Worduuid:af860be0-f082-4491-81f2-53e76c9f470cuuid:7d88ba36-1801-42a1-93a7-da36f071dd3a9xmlANTIARTHRITIC ACTIVITY OF PACAR AIRismail - [2010]Adobe PDF Library 11.0D:20160408131818home
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.9, No.3, pp 131-137, 2016
Antiarthritic Activity of Pacar Air (Impatiens balsamina Linn.) Herb Extract in Animal Model of Rheumatoid Arthritis – An Autoimmune Disease Hariyanto Ih*, Indri Kusharyanti1,21, Maria Immaculata Iwo2 1Department of Pharmacy, Faculty of Medicine, Tanjungpura University, Pontianak, Indonesia 2School of Pharmacy, Bandung Institute of Technology (ITB), Bandung, Indonesia Abstract: The objective of this study was to investigate the activity of Impatiens balsamina herb in animal model of rheumatoid arthritis. The active compounds of leaf and stem of Impatiens balsamina Linn. were extracted using ethanol 96% by maceration method. Anti-arthritis activity of the test extracts was determinedin rat adjuvant-induced arthritis (AIA) model. The rats were injected with Complete Freund's Adjuvant (CFA) intraplantarly to induce arthritic animal model. The anti-arthritic effect of the extracts was determined by measurement of the paw volume, joint edema, and TNF-α levels determined using ELISA technique. The rats were successfully arthritis induced using 0.25 mL of CFA. The administration of extract for 14 days started from day 8.Highest inhibitionpercentage was caused by high dose of Impatiens balsaminaextract (500 mg/kg bw)with inhibition percentagefor paw and joint edemawere 29.6% and 24.9%, respectively. The TNF-α levels in all doses of extract groupsdecreased and significantly lower (p<0.05) compared to that of control. Impatiens balsamina extract has immunosuppressive activity and able to reduce arthritis symptoms in adjuvant induced arthritisrat model. Impatiens balsamina extract also has the activity to minimize symptoms of arthritis, so it is a potentially alternative drug for rheumatoid arthritis. thduring chronic arthritic condition significantly (p<0.05) reduced the total volume of paw and joint edema while no effect onbody weightKeywords: Complete Freund’s Adjuvant (CFA), Impatiens balsamina, rheumatoid arthritis, TNF-α. Introduction Rheumatoid arthritis (AR) is a systemic autoimmune disease characterized by chronic polyarthritis, progressive inflammation and synovial proliferation followed by erosion of the joints and cartilage1. Rheumatoid arthritis (AR) itself is one of the autoimmune diseases and arthritis that often occurs affects more than 1.3 million people in the United States with 75% of whom are women2. Impatiens balsamina was used in traditional Chinese medicine, Taiwan and Thailand to treat arthritis, fractures, and superficial infectionherb has anti-inflammatory activity in carrageenan-induced mice3. Another study showed Impatiens balsamina 4. Impatiens balsamina plants also contains high naphthoquinone. Research onnaphthoquinone shows immunosuppressant activity by nitric oxide from macrophages potentially carcinogenic with immunosuppressive effects by 98%5. This research will assess anti-arthritic effects of Impatiens balsamina Ethanolic extract in Adjuvant-Induced Arthritis (AIA) animal models, which is one of the rheumatoid arthritis animal models. Experimental Materials Stems andleaves of Impatiens balsamina Linn., ethanol 96%, distilled water, hydrochloric acid, sulfuric acid, isopropanol, toluene, chloroform, ammonia, dragendorff reagent, Mayer reagent, magnesium powder, amyl alcohol, solution of Fe(III) chloride, gelatin, sodiumchloride 0,9%, Chinese ink Pelikan®B-17,thin-layer chromatography plates (GF254), Carboxymethylcellulose sodium, Methylprednisolone (PT. Gracia Pharmindo), acetate acid, sterilized bidistilled water, Rat TNF alpha ELISA Ready-Set-Go!® (eBioscience®) kit, phosphate buffer saline (PBS), Tween 20, Complete Freund’s Adjuvant (CFA) (Sigma®). Instruments Grinders, oven, analytical scale, a set of distillation, rotary evaporator (Buchi Rotavapor R-215 and Buchi Heatingbath B-491), UV-Vis spectrophotometer (Hewlett Packard 8452), ELISA reader (Thermo Scientific Multiskan®), Plethysmometer (Ugo Basile 37140), Animal Female Wistar rats aged 8 weeks obtained from the Animal Laboratory, School of Pharmacy,Bandung Institute of Technology (ITB) Plants Preparation Impatiens balsamina plant was taken from Kuala Dua village, Rasau Jaya district, Kubu Raya Regency, West Kalimantan. Determination of the plant were performed at Biology Laboratory of Mathematics and Natural sciences, University of Tanjungpura, Pontianak. Extraction Crude plant powder was extracted by maceration with 96% ethanol, which previously had been redistilled. Maceration is done for 4 x 24 hours and filtered as well as replacing the solvent every 24 hours. Extract was concentrated using rotary evaporator to obtain a thick extract. Anti-Arthritis Effect Assessment Extract effects were conducted in vivo using Wistar strain female rats aged 8 weeks. Assesment of Rheumatoid arthritis animal model is divided into three phases. Test phase including induction phase, treatment phase, and evaluation of test results. Induction Phase Induction of arthritis was conducted using Adjuvant-Induced Arthritis (AIA) which has been modified by Woodefootpad of the left leg of rats. CFA is a suspension that contains antigen of Mycobacterium tuberculosis (H37Ra, ATCC 25177) at a concentration of 1 mg/ mL suspension. Before it is injected, CFA suspension were homogenized by vortex. Before the injections, the rats were weighed, paw and joint thickness were also measured, as well as serum on day 0 (T6. Each test animals were injected intraplantar with 0.25 mL of Complete Freund's Adjuvant (CFA) on the 0) Treatment Phase The Administration of the test extract was conducted on day 8thbased on the clinical sign of arthritis and the inflammatory reaction that shown. Clinical signs of arthritis which is characterized by the appearance of chronic phase (in day 8th) such as the increasing of paw volume and joint edema that occurs after the acute phase (in day 4th- 5th). After the expected clinical symptoms appear, on day 8, the animals were randomized into 4 groups, i.e. control group (1% Na CMC), methylprednisolone group (15 mg/kg bw), Ethanolic Extract of Impatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaImpatiens balsaminaEvaluation phase The evaluation is conducted to assess outcome of therapy and the development of test conditions treated animals. Evaluation is done by observing the daily body weight, paw volume, and joint edema in each animal. Serum samples were taken on day 5 via tail vein to measure TNF-α level on day 5 (T, to measure TNF-α level on day 21 (T5) and at the end of the test21). Observation of Paws volume and Joints Edema. During anti-arthritis effect assessment, paws and joints thickness were observed for 14 days. Paw volume were measured every day from the first day after induction by comparing the increase or decrease percentage in paw volume from day to day as compared to day 0, i.e. before induction. Joints thickness were also measured every day compared to the joints thickness on day 0. Total volume of edema of the day 8 to day 21 of each group was calculated in arbitrary units to obtain the value of Area Under the Curve (AUC) and the inhibition percentage is calculated as: Edema inhibition (%)= AUC values for each group were compared and statistically analyzed with ANOVA and significance of the data were determined. Determination ofTNF-α Levels Each of these animals had serum samples taken from the tail vein on day 0 (Twas determined by ELISA Technique. 0), day 5 (T5), and day 21 (T21). TNF-α level Results and Discussion Anti-arthritis Effect Testing Results of Extract Animal model of rheumatoid arthritis (AR) is prepared by Adjuvant-Induced Arthritis (AIA) method, using Complete Freund's Adjuvant (CFA) as the immunogen. Adjuvant Induced Arthritis is commonly used in AR experiments, namely by inducing arthritis using a single injection of CFA intradermally. Complete Freund's Adjuvant contains heat-killed Mycobacterium tuberculosis suspended in mineral oil. Bacteria contained in the CFA will amplify the signal to be received by T cells and activate the T cells, thereby increasing immune response that may caused chronic inflammation. AIA animal model is marked by the emergence of two (2) phases, namely the acute phase and chronic phase. Induction of arthritis is successful, if animal models continues to experience chronic phase after acute phase has passed. Assessment for the category of animals who experience chronic phase is characterized by an increase in swelling or edema volume on the paw and joints that injected, after a decline in the volume of edema in the acute phase. Based on research by Weichmanth
to day 6th
and followed by the onset of the chronic phase between days 9th
-12th
after CFA induced. 7rheumatoid arthritis animal model, acute phase will occur between day 4
In this study, administration of the test substance wasstarted on day 8th
after CFA induction, which isthe arthritishas started that is characterized by the onset of the chronic phase and the test substance administered daily for 14 days, with a total of 21 days’ observation after CFA induction.
Control group shows an increase in the paw volume at day 4th
and increased joints edema at day 5th
, which gradually decrease. The increasein paw volume and joints thicknessis started again between day 8th
and day 9th
. This suggests that the acute inflammatory phase occurs between the day 4 day 8
th and 5th, followed by a chronic phase that occurs between theth and 9th. In the control group, an increase in the volume of swollen paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8paw were highly significant (p <0.05) on day 8Description : MP = Methylprednisolone EPA I = Impatiens balsamina extract dose I(250 mg/kg bw) EPA II = Impatiens balsamina extract dose II (500mg/kg bw) Figure 1. Percent increase in leg swelling curves of AIA rats after administration of the test extract Description : MP = Methylprednisolone EPA I = Impatiens balsamina extract dose I(250 mg/kg bw) EPA II = Impatiens balsamina extract dose II (500mg/kg bw) Figure 2. Curves percent increase in thick joints of AIA rats after administration of the test extract Ethanolic Extract of Impatiens balsamina dose 250 mg/kg bw (EPA I), and Ethanolic Extract of Impatiens balsamina dose 500 mg/kg bw (EPA II) was administered from day 8th thsignificantly reduces paw volume (p<0.05) compared to control group. Meanwhile, comparison group given Methylprednisolone (MP) shows a decrease in paw volumethat was significantly different (p<0.05) than the control group and the group extracts. Inhibition percentage of paw volume can be seen in Table 1. to 21Figure 3.Total Edema in Paw of AIA Rats during the administration of Extract Table 1. AIA rats paw edema inhibition after extract administration
Test groups
Dose (mg/kg bw)
Inhibition of paw edema (%)
Control
-
0
MP
15
75.7
EPA I
250
28.5
EPA II
500
29.6
Description: MP = Methylprednisolone EPA = Impatiens balsamina herb extract Similar as the value of total edema in paw, total of joint edema from day 8th
to day 21th
can be obtained from the calculation of Area Under the Curve (AUC). Increase in joint edemaand percent inhibition of increase in joint edema of each treatment group can be calculated. Percent inhibition is shown on table 2.
Figure 4. Total of joint edemaof AIA ratsafter administration of test extracts Table 2. Inhibition ofJointedemaafter administration of the test extract
Test groups
Dose (mg/kg bw)
Inhibition of increase in thickness Joints(%)
Control
-
0
MP
15
74.37
EPA I
250
18.73
EPA II
500
24.92
MP = Methylprednisolone EPA = Impatiens balsamina herb extract Test extracts used from day 8th
to day 21th
, reduces joint thickness significantly (p<0.05) compared to the control group. Ethanolic Extract of Impatiens balsaminaat dose 500 mg/kg bwhas inhibitory effect or the effect of decreasing thickness joints better, compared toEthanolic Extract of Impatiens balsamina dose 250 mg/kg bw. However, the decline is best demonstrated by a comparison group of animals which were given methylprednisolone with inhibition values of 74.37% that was significantly different (p<0.05) than the control group and the group of test extracts.
In addition to the presence of immune cells that plays a role in the immune response, there is also the role of protein molecules as a signal conductor called cytokines. Cytokines are released by cells in response to a stimulus and will induce an immune response through its binding to specific receptors located on the membrane of immune cells8. Cells which play a role in the pathogenesis of rheumatoid arthritis is T and B Lymphocytes. B lymphocytes produces autoantibody against collagen type II. Autoreactive antibodies will form a complex with self-antigens in the joints, causing type III hypersensitivity reaction which ends in local inflammation9. In a state of inflammation, several proinflammatory cytokines such as TNF-α, IL-Iβ and IL-6 are secreted by the cellular immune system which will stimulate the migration of macrophages and neutrophils to areas of inflammation and cartilage, resulting in worsening joint damage. Thus, we need to test the activity of the extract in suppressing the secretion of TNF-α in animal models of arthritis, to know how does this extract perform. Table 3.Levels of TNF-α for testing the effect of test extract on AIA rats
Test groups
Dose (mg/kg bw)
TNF-α level (pg/mL)
H0
H5
H21
Control
0
-
15.444 ± 2.694
18.333 ± 1.764
MP
15
-
12.556 ± 1.388
- **
EPA I
250
-
15.667 ± 1.333
11.444 ± 1.018 **
EPA II
500
-
14.111 ± 2.037
10.333 ± 0.667 **
Description: ** = Significantly different to controls (p<0.01) - = Not Detected H0 = Day 0 or before induction H5 = Day 5 after induction H21 = Day 21 after induction From Table 3 above, CFA induction and the effect of test substances on levels of TNF-α in the blood can be seen. On day 0, i.e. before induced, TNF-α levels in the blood does not go undetected. However, 5 days after induction, where there is an acute inflammatory phase, each test group yields TNF-α levels which were insignificant with the control group (p<0.05). On day 21 after induction or after 14 days of administration of the test substance, the levels of TNF-α each group shows a decrease, except for the control group which tend to increase. In both groups of animals given Ethanolic Extract of Impatiens balsamina, their TNF-α levels were significantly different than the control group. Decreased levels of TNF-α is best shown in groups of animals treated with methylprednisolone as a comparator drug, i.e. the levels of TNF-α were not detected as TNF-α levels in normal animals before induced. The levels may be too small as it cannot be detected by ELISA reader. Rheumatoid arthritis is an autoimmune disease that is mediated by the activity of phagocytic cells, T cells and B cells and is characterized by increased proinflammatory cytokine TNF-α, IL-Iβ and IL-610. In AIA animal model, an increase in proinflammatory cytokines TNF-α is known to cause rheumatoid arthritis. According to Janeway8, Tumor Necrosis Factor-α (TNF-α) is a proinflammatory cytokine produced by macrophages, mast cells and NK cells. Because of the ability of the extract in suppressing the production of TNF-α and non-specific immune response, the suspected mechanism of action of the extracts of the cells is to suppress the activity of macrophages and other innate immune cells. Conclusion Ethanolic Extract of Impatiens balsamina with doses of 250 and 500 mg/kg bw have immunosuppressive activity. The extract also had lower activity in Adjuvant Induced Arthritis (AIA) animal model, best percent inhibition is shown by Ethanolic Extract of Impatiens balsamina dose 500 mg/kg bw. Ethanolic Extract of Impatiens balsamina also has the potential to be developed as an alternative medicine for the treatment of rheumatoid arthritis. Acknowledgement Acknowledgements submitted to the research grant from Directorate General of Higher Education, Indonesia (DIRJEN DIKTI) through Decentralization on funding research grants awarded (HIBAH PEKERTI)in 2014. References
1. Wells, G. A., J. A. Singh, Biologics for Rheumatoid Arthritis: An Overview of Cochrane Reviews, Cochrane database system rev., John Wiley & Sons, Ltd, New York,2009
2. Ruderman, Eric and Siddharth, T., Rheumatoid Arthritis, American College of Rheumatology, Atlanta.2012
3. Ding, Z.S., Jiang, F.S., Chen, N .P., Lv, G. Y., and Zhu, C.G., Isolation and Identification of an Antitumor Component from Leaves of Impatiens balsamina, Molecules, 2008, 13, 220-229.
4. Sumiwi, S. A., Anas, S. and Rachmayanti, Aktivitas Antiinflamasi Ekstrak Etanol Tanaman Impatiens balsamina (I. balsamina Linn.),2007,
http://farmasi.unpad.ac.id/farmaka/v3n2/sriadi.pdf
.(accessed 20th of May 2014)
5. Kitagawa, R. Rodrigo., et al., Antitumor and immunomodulatory effects of the naphthoquinone 5-methoxy-3,4-dehydroxanthomegnin, Brazilian Journal of Pharmacognosy21,2011,6, 1084-1088
6. Woode, E., G.K. Ainooson, E. Boakye-Gyasi, C. Ansah., D.D. Obiri, G.A. Koffour, A.Y. Mensah and M. Duwiejua, Anti-arthritic and Antioxidant Properties of the Ethanolic Stem Bark Extract of Newbouldia laevis (P. Beauv.) Seaman ex Bureau (Bignoniaceae), J. Med. Plants Res., 2009,2, 180-188
7. Weichman, B. M., Rat Adjuvant Arthritis: A Model of Chronic Inflammation. In: Pharmacological Methods in the Control of Inflammation, Chang, J. Y. and A. J. Lewis (Eds.). Alan R. Liss, Inc., New York, 1989, 363-380.
8. Janeway, Charles, 7th Ed. Janeway’s Immunobiology, Kenneth, M., Travers, P. and Walport, M., Garland Science, Taylor and Francis Group, New York, 2008,2-27.
9. Goldsby, R. A., T. J. Kindt, B. A. Osborne and J. Kuby, Immunology, W. H. Freeman, New York,2009, 383-385, 460-477.
10. Gonzalez-Rivera, T. C., Anti – Tumor Necrosis Factor, Reviewed by The American College of Rheumatology Communication and Marketing Committee, American College of Rheumatology, Atlanta,2012.